Table 2

Characteristics of included studies and assessment of the risk of biasa
Study Study Characteristics Assessment of the risk of bias
Population Nb % Male Baseline CD4 Baseline VL Follow-up time Eligibility HSV-2 Ascertain-ment Endpoints Confoun-ding Analysis Attrition OVERALL Impact of biasc
Barnabas 2011 Men, International 88 100 NR NR NR Moderate Low Low Moderate Moderate Moderate Moderate
Cachay 2007 Male HIV seroconverters, USA 294 100 497 4.97 205 days Low Low Low Low Moderate Low Low N/A
Cachay 2008 Male HIV seroconverters, USA 119 100 520 5.04 779 days Low Low Moderate Low Moderate Low Low N/A
Crum-Cianflone 2006 USA 367 92 499 NR NR Low Moderate Moderate High Moderate Moderate High ?
Nagot 2008 Women, Burkina Faso 140 0 443 4.48 12 weeks Moderate Low Low Low Moderate Low Low N/A
Roxby 2011 Pregnant women, Kenya 296 0 422 4.75 18 months Moderate Low Low Moderate Moderate Moderate Moderate
Suligoi 2001 HIV sero-converters, Italy 380 78 NR NR 7.8 years Low Low Moderate High Moderate High High ?

aMedian values are reported unless noted otherwise. When values were not reported for overall population, a weighted average was taken.

bN reported for patients included in relevant comparisons only.

cAssessed only for studies deemed at moderate or high risk of bias. N/A = not applicable (ie. study at low risk of bias), ↓ indicates bias towards null, ? indicates uncertain bias of direction.

Tan et al.

Tan et al. BMC Infectious Diseases 2013 13:502   doi:10.1186/1471-2334-13-502

Open Data